The company has received final approval following the expiration of Roche’s patent on December 28, 2007, and plans to launch its product shortly.
Kytril (granisetron hydrochloride) tablets, 1mg (eq to 1mg base) is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, and radiation.